Introduction: We report the oncological outcome after laparoscopic radical cystectomy (LRC) and standard laparoscopic pelvic lymph node dissection (PLND) without neoadjuvant or adjuvant therapy in the treatment of bladder cancer with a median follow-up of 32 months. Materials and Methods: From September 2006 to January 2011, 40 consecutive patients underwent an LRC and standard laparoscopic PLND, and were included in this prospective observational cohort study. No patient received neoadjuvant or adjuvant therapy. Demographic, perioperative, complication, histopathologic and survival data were collected and analyzed. Results: The 2002 TNM staging for the tumors were: pT0, 4 cases; pTis, 5 cases; pT1, 4 cases; pT2, 7 cases; pT3, 13 cases; pT4, 7 cases. Positive surgical margins were reported in 3 patients (7.5%) and lymph node involvement in 9 patients (23.7%). No patient was lost to follow-up. The overall, cancer-specific and recurrence-free survival rates were 53, 73 and 70% with a median follow-up of 32 months. Eleven patients (27.5%) died of metastatic disease or local recurrence. Nonorgan-confined disease (≥pT3) and primary lymph node involvement (pN+) were significantly associated with worse overall, cancer-specific and recurrence-free survival rates. Conclusion: We report acceptable mid-term and promising long-term oncological outcome after LRC and standard laparoscopic PLND without neoadjuvant or adjuvant therapy.

Keywords:
Bladder cancer, Laparoscopic radical cystectomy, Oncologic outcome
1.
Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666-675.
2.
Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN, Danuser H, Markwalder R, Studer UE: Radical cystectomy for bladder cancer today - a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003;21:690-696.
3.
Hautmann RE, de Petriconi RC, Pfeiffer C, Volkmer BG: Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1,100 patients. Eur Urol 2012;61:1039-1047.
4.
Sanchez de Badajoz E, Gallego Perales JL, Reche Rosado A, Gutierrez de la Cruz JM, Jimenez Garrido A: Radical cystectomy and laparoscopic ileal conduit (in Spanish). Arch Esp Urol 1993;46:621-624.
5.
Berger A, Aron M: Laparoscopic radical cystectomy: long-term outcomes. Curr Opin Urol 2008;18:167-172.
6.
European Association of Urology: Guideline on bladder cancer - muscle invasive and metastatic. Arnhem, European Association of Urology, 2012.
7.
Chade DC, Laudone VP, Bochner BH, Parra RO: Oncological outcomes after radical cystectomy for bladder cancer: open versus minimally invasive approaches. J Urol 2010;183:862-869.
8.
Rassweiler J: Laparoscopic radical cystectomy - where are we really? Eur Urol 2008;54:19-20.
9.
Dindo D, Demartines N, Clavien PA: Classification of surgical complications: a new proposal with evaluation in a cohort of 6,336 patients and results of a survey. Ann Surg 2004;240:205-213.
10.
Cathelineau X, Arroyo C, Rozet F, Barret E, Vallancien G: Laparoscopic assisted radical cystectomy: the Montsouris experience after 84 cases. Eur Urol 2005;47:780-784.
11.
Huang J, Lin T, Liu H, Xu K, Zhang C, Jiang C, Huang H, Yao Y, Guo Z, Xie W: Laparoscopic radical cystectomy with orthotopic ileal neobladder for bladder cancer: oncologic results of 171 cases with a median 3-year follow-up. Eur Urol 2010;58:442-449.
12.
Konety BR, Allareddy V, Herr H: Complications after radical cystectomy: analysis of population-based data. Urology 2006;68:58-64.
13.
Shabsigh A, Korets R, Vora KC, Brooks CM, Cronin AM, Savage C, Raj G, Bochner BH, Dalbagni G, Herr HW, Donat SM: Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol 2009;55:164-174.
14.
Nathan H, Pawlik TM: Limitations of claims and registry data in surgical oncology research. Ann Surg Oncol 2008;15:415-423.
15.
Rassweiler J, Tsivian A, Kumar AV, Lymberakis C, Schulze M, Seeman O, Frede T: Oncological safety of laparoscopic surgery for urological malignancy: experience with more than 1,000 operations. J Urol 2003;169:2072-2075.
16.
Herr HW, Faulkner JR, Grossman HB, Natale RB, deVere White R, Sarosdy MF, Crawford ED: Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol 2004;22:2781-2789.
17.
Metzger T, Thalmann GN, Zehnder P: Lymphadenectomy for bladder cancer: current status and controversies (in German). Urologe A 2012;51:310-318.
18.
Vieweg J, Gschwend JE, Herr HW, Fair WR: Pelvic lymph node dissection can be curative in patients with node positive bladder cancer. J Urol 1999;161:449-454.
19.
Zehnder P, Studer UE, Skinner EC, Dorin RP, Cai J, Roth B, Miranda G, Birkhauser F, Stein J, Burkhard FC, Daneshmand S, Thalmann GN, Gill IS, Skinner DG: Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. J Urol 2011;186:1261-1268.
20.
Abol-Enein H, Tilki D, Mosbah A, El-Baz M, Shokeir A, Nabeeh A, Ghoneim MA: Does the extent of lymphadenectomy in radical cystectomy for bladder cancer influence disease-free survival? A prospective single-center study. Eur Urol 2011;60:572-577.
21.
Wright JL, Lin DW, Porter MP: The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy. Cancer 2008;112:2401-2408.
22.
Herr HW, Smith JA, Montie JE: Standardization of radical cystectomy: time to count and be counted. BJU Int 2004;94:481-482.
23.
Rink M, Lee DJ, Kent M, Xylinas E, Fritsche HM, Babjuk M, Brisuda A, Hansen J, Green DA, Aziz A, Cha EK, Novara G, Chun FK, Lotan Y, Bastian PJ, Tilki D, Gontero P, Pycha A, Baniel J, Mano R, Ficarra V, Trinh QD, Tagawa ST, Karakiewicz PI, Scherr DS, Sjoberg DD, Shariat SF: Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. BJU Int 2013;111:E30-E36.
24.
Skinner EC, Stein JP, Skinner DG: Surgical benchmarks for the treatment of invasive bladder cancer. Urol Oncol 2007;25:66-71.
25.
DeGer S, Peters R, Roigas J, Wille AH, Tuerk IA, Loening SA: Laparoscopic radical cystectomy with continent urinary diversion (rectosigmoid pouch) performed completely intracorporeally: an intermediate functional and oncologic analysis. Urology 2004;64:935-939.
26.
Simonato A, Gregori A, Lissiani A, Bozzola A, Galli S, Gaboardi F: Laparoscopic radical cystoprostatectomy: our experience in a consecutive series of 10 patients with a 3 years follow-up. Eur Urol 2005;47:785-790, discussion 790-792.
27.
Haber GP, Gill IS: Laparoscopic radical cystectomy for cancer: oncological outcomes at up to 5 years. BJU Int 2007;100:137-142.
28.
Ha US, Kim SI, Kim SJ, Cho HJ, Hong SH, Lee JY, Kim JC, Kim SW, Hwang TK: Laparoscopic versus open radical cystectomy for the management of bladder cancer: mid-term oncological outcome. Int J Urol 2010;17:55-61.
29.
Gillion N, Xylinas E, Durand X, Ploussard G, Vordos D, Allory Y, Hoznek A, de la Taille A, Abbou CC, Salomon L: Mid-term oncological control after laparoscopic radical cystectomy in men: a single-centre experience. BJU Int 2011;108:1180-1184.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.